ID

34178

Description

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02392455

Link

https://clinicaltrials.gov/show/NCT02392455

Keywords

  1. 1/15/19 1/15/19 -
  2. 5/14/19 5/14/19 -
Copyright Holder

GSK group of companies

Uploaded on

January 15, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Non-Small-Cell Lung NCT02392455

Eligibility Carcinoma, Non-Small-Cell Lung NCT02392455

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age 18 or older
Description

ID.1

Data type

boolean

men and women locally advanced, metastastic and/or recurrent nsclc with adenocarcinoma histology for which vargatef treatment is indicated according to summary of product characteristics (smpc)
Description

ID.2

Data type

boolean

after first line therapy; second-line therapy not yet started
Description

ID.3

Data type

boolean

standard 21-day-cycles docetaxel treatment according to smpc possible
Description

ID.4

Data type

boolean

written informed consent
Description

ID.5

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
contraindications according to the smpc of vargatef or docetaxel
Description

ID.6

Data type

boolean

more than one systemic therapy for treatment of nsclc in palliative setting
Description

ID.7

Data type

boolean

current partcipation in another non-interventional study or a clinical trial
Description

ID.8

Data type

boolean

pregnancy
Description

ID.9

Data type

boolean

breastfeeding
Description

ID.10

Data type

boolean

Similar models

Eligibility Carcinoma, Non-Small-Cell Lung NCT02392455

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
age 18 or older
boolean
ID.2
Item
men and women locally advanced, metastastic and/or recurrent nsclc with adenocarcinoma histology for which vargatef treatment is indicated according to summary of product characteristics (smpc)
boolean
ID.3
Item
after first line therapy; second-line therapy not yet started
boolean
ID.4
Item
standard 21-day-cycles docetaxel treatment according to smpc possible
boolean
ID.5
Item
written informed consent
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
contraindications according to the smpc of vargatef or docetaxel
boolean
ID.7
Item
more than one systemic therapy for treatment of nsclc in palliative setting
boolean
ID.8
Item
current partcipation in another non-interventional study or a clinical trial
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
breastfeeding
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial